Meridiem Capital Partners LP Invests $1.46 Million in Beta Bionics, Inc. $BBNX

Meridiem Capital Partners LP purchased a new position in shares of Beta Bionics, Inc. (NASDAQ:BBNX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 73,386 shares of the company’s stock, valued at approximately $1,458,000. Meridiem Capital Partners LP owned approximately 0.17% of Beta Bionics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Beta Bionics during the first quarter valued at about $95,000. Goldman Sachs Group Inc. bought a new stake in Beta Bionics in the 1st quarter worth about $715,000. Woodline Partners LP purchased a new stake in Beta Bionics in the 1st quarter valued at about $1,530,000. Strs Ohio purchased a new stake in Beta Bionics in the 1st quarter valued at about $29,000. Finally, Rhumbline Advisers bought a new position in shares of Beta Bionics during the 1st quarter worth approximately $158,000.

Beta Bionics Price Performance

Shares of BBNX traded up $0.35 during mid-day trading on Friday, hitting $10.46. The stock had a trading volume of 103,373 shares, compared to its average volume of 1,317,591. Beta Bionics, Inc. has a 52 week low of $8.89 and a 52 week high of $32.71. The business has a fifty day moving average price of $15.90 and a 200-day moving average price of $22.07. The firm has a market cap of $464.30 million, a P/E ratio of -5.35 and a beta of 5.60.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.The company had revenue of $32.12 million during the quarter.

Insider Transactions at Beta Bionics

In related news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the sale, the chief financial officer directly owned 42,614 shares in the company, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Mike Mensinger sold 7,800 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.61, for a total value of $230,958.00. Following the completion of the transaction, the insider directly owned 82,952 shares of the company’s stock, valued at $2,456,208.72. The trade was a 8.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 34,705 shares of company stock valued at $945,653 in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BBNX shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a report on Thursday, January 15th. Lake Street Capital set a $20.00 target price on Beta Bionics in a research report on Wednesday, February 18th. Stifel Nicolaus lowered their target price on Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. TD Cowen assumed coverage on shares of Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price target on the stock. Finally, UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $23.20.

Beta Bionics Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.